BPAP Titration Study Recommendations for Central Sleep Apnea

Patient Selection and Initial Therapy

• The American Academy of Sleep Medicine recommends starting with standard CPAP as first-line therapy for complex sleep apnea, with BPAP-ST as the next step before considering ASV, for patients with central sleep apnea and normal ejection fraction 1
• BPAP with backup rate represents the appropriate first-line advanced PAP therapy for patients with central sleep apnea, as it allows assessment of response to less complex therapy before advancing to ASV 1

Contraindications and Safety Considerations

• The American Academy of Sleep Medicine explicitly states that ASV is contraindicated only in patients with heart failure and ejection fraction ≤ 45% due to demonstrated increased mortality risk from the SERVE-HF trial 2, 3
• The American Academy of Sleep Medicine recommends obtaining ejection fraction before considering ASV, as this is the critical safety determinant 1

Alternative Therapies and Clinical Pitfalls

• Oxygen is considered an alternative only when PAP therapies fail or are contraindicated, and is not appropriate as primary therapy for central sleep apnea 1
• The 2022 AHA/ACC/HFSA guidelines discuss cardiac optimization in the context of heart failure with reduced ejection fraction, which is not applicable to patients with normal ejection fraction 6
• The American Academy of Sleep Medicine suggests that ASV can be considered if CPAP or BPAP fails, particularly in patients with normal ejection fraction (>45%) 4, 1

Expected Outcomes and Monitoring

• If BPAP proves inadequate (AHI remains >10-15/hr), then progression to ASV titration is appropriate and safe given normal EF 1